Research ArticleBrief Report
Immune Therapy and β-Cell Death in Type 1 Diabetes
Jasmin Lebastchi, Songyan Deng, Amir H. Lebastchi, Isabel Beshar, Stephen Gitelman, Steven Willi, Peter Gottlieb, Eitan M. Akirav, Jeffrey A. Bluestone, Kevan C. Herold
DOI: 10.2337/db12-1207 Published 1 May 2013
Jasmin Lebastchi
1Departments of Immunobiology and Internal Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut
Songyan Deng
1Departments of Immunobiology and Internal Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut
Amir H. Lebastchi
1Departments of Immunobiology and Internal Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut
Isabel Beshar
1Departments of Immunobiology and Internal Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut
Stephen Gitelman
2Department of Pediatrics, University of California, San Francisco, San Francisco, California
Steven Willi
3Department of Endocrinology, Children’s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Peter Gottlieb
4Department of Internal Medicine, University of Colorado at Denver, Aurora, Colorado
Eitan M. Akirav
5Diabetes and Obesity Center, Winthrop University Hospital, Mineola, New York
Jeffrey A. Bluestone
6Department of Internal Medicine, University of California, San Francisco, San Francisco, California
Kevan C. Herold
1Departments of Immunobiology and Internal Medicine and Surgery, Yale University School of Medicine, New Haven, Connecticut
Supplementary Data
Files in this Data Supplement: